Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test (DMIA)

  • End date
    May 31, 2025
  • participants needed
  • sponsor
Updated on 4 October 2022


European, multicenter clinical trial with VisioCyt®, an in vitro diagnostic medical device. VisioCyt® is an innovative solution for the early diagnosis of bladder cancer.


VisioCyt® is based on a patented technology, combining bright-field imaging and artificial intelligence, from a simple urine sample from which the cells are extracted .

The main objective of the study is to demonstrate the medical superiority of the VisioCyt® test versus conventional cytology for detecting recurrence of bladder tumors, in patients monitoring non-muscle infiltrating bladder tumors at high and very high risk of progression

Condition Non-muscle Invasive Bladder Cancer (NMIBC)
Treatment VisioCyt®
Clinical Study IdentifierNCT05176145
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Age ≥18 years old and autonomous
Patient understanding national language well and able to understand the protocol
Patient information and informed consent signature before the start of the study
Patients under surveillance of Non-muscle invasive bladder cancer (NMIBC) at high and very high risk of progression, whatever the stage on the basis of a histological result. The primary diagnosis should be less than or equal to 12 months

Exclusion Criteria

Patients who have had total bladder resection or bladder reconstruction
Age <18 years old
Person deprived of liberty or under guardianship (including curatorship)
Bladder cancer outside of urothelial carcinoma
Associated high urinary tract carcinoma
Kidney transplant patient (BK virus)
Pelvic radiotherapy patient (prostate cancer)
Patients with or under surveillance of a muscle-infiltrating bladder tumor
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note